NewsfeedFollowed Companies

Roche's Competitors, Revenue, Number of Employees, Funding and Acquisitions

Roche discovers, develops and provides diagnostic and therapeutic products and services.

Roche's headquarters is in Basel... Read more

Annual Revenue

Employees

Severin Schwan's photo - CEO of Roche

CEO

Severin Schwan

CEO Approval Rating

76/100

OVERVIEW

Founded:

1896

Headquarters:

BaselBasel-Country

Status:

PublicIndependent Company of SIX Swiss ExchangeROG

Industry Sector:

Biotechnology

SIC Code:

2836NAICS listing »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is GSK a competitor of Roche?

I don't know

Trending News for Roche and Roche's Competitors

December 12, 2019

Pharmafile

Roche's subcutaneous Perjeta/Herceptin combo proves non-inferior to IV formulation in HER2-positive early breast cancer

New Phase 3 data from Roche has shown that its subcutaneously-delivered formulation of Perjeta (pertu... See more »

December 12, 2019

Pharamceutical Technology

Novartis and Forendo enter into tissue hormone-focused licensing collaboration

Finland-based Forendo Pharma has announced it has signed a licensing and collaboration agreement with... See more »

December 12, 2019

BioPortfolio

Lilly launches first of its kind trial for RET fusionpositive NSCLC

Selpercatinib was designed to inhibit native RET signaling as well as anticipated acquired resistance... See more »

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

Novartis is seen as one of Roche's top competitors. Novartis was founded in Basel, Basel-City} in 1996. Novartis is in the Pharmaceuticals industry. Compared to Roche, Novartis generates $49.4B more revenue.

Merck is Roche's #2 competitor. Merck was founded in 1891, and its headquarters is in Kenilworth, New Jersey. Merck is in the Pharmaceuticals field. Merck has 25,052 fewer employees than Roche.

Bristol Myers Squibb is Roche's #3 rival. Bristol Myers Squibb is headquartered in New York, New York, and was founded in 1858. Like Roche, Bristol Myers Squibb also competes in the Biotechnology industry. Bristol Myers Squibb generates 2,606% the revenue of Roche.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

Severin Schwan

CEO

- -
94,052
$0
$927.4M
1

Vasant Narasimhan

CEO

74/100
118,393
- -
$50.3B
2

Kenneth C. Frazier

Chairman & CEO

71/100
69,000
- -
$46B
3

Giovanni Caforio

Chairman & CEO

84/100
23,300
- -
$24.2B
4

Alex Gorsky

Chairman & CEO

65/100
135,100
- -
$81.7B
5

David A. Ricks

Chairman & CEO

69/100
38,680
- -
$24.9B
6

Emma Walmsley

CEO

72/100
99,827
- -
$40.4B
7

Albert Bourla

CEO

83/100
92,400
- -
$53B
8

Umang Vohra

CEO

65/100
12,235
- -
$1.9B
9

Miles D. White

Chairman & CEO

62/100
103,000
$6.9M
$31.4B
10

Omar Ishrak

Chairman & CEO

91/100
86,000
- -
$30.9B
The top 10 competitors in Roche's competitive set are Novartis, Merck, Bristol Myers Squibb, Johnson & Johnson, Eli Lilly, GSK, Pfizer, Cipla, Abbott and Medtronic. Together they have raised over 6.9M between their estimated 784.1K employees. Roche has 94,052 employees and is ranked 5th among it's top 10 competitors. The top 10 competitors average 79,271.

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$927.4M

Roche's revenue is the ranked lowest among it's top 10 competitors. The top 10 competitors average 35.1B. Over the last four quarters, Roche's revenue has decreased by $-1100000. Specifically, in Q3 2019's revenue was $221.8M; in Q2 2019, it was $242.9M; in Q1 2019, it was $239.8M; in Q4 2018, Roche's revenue was $222.9M.

Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Promedior, Inc.

Nov 2019

Source »
$390M
Promedior is a clinical-stage biotechnology company that develops and commercializes novel therapeutics for the treatment of fibrotic disorders.
Spark Therapeutics, Inc.

Feb 2019

Source »
$4.3B
Spark Therapeutics develops gene therapies for the treatment of hemophilia and neurodegenerative diseases.
Tusk Therapeutics Ltd.

Sep 2018

Source »
$81.9M
Tusk Therapeutics develops and commercializes therapeutic antibodies for the treatment of cancer.
Flatiron Health, Inc.

Feb 2018

Source »
$1.9B
Flatiron Health is a healthcare technology company that focuses on accelerating cancer research through clinical data management.
Ignyta, Inc.

Dec 2017

Source »
$1.7B
Ignyta develops and commercializes targeted molecule therapies for the treatment of cancer.

These are all the companies that Roche has acquired. Roche has acquired 18 companies and its latest acquisition was Promedior, Inc. in Nov 2019. Promedior is a clinical-stage biotechnology company that develops and commercializes novel therapeutics for the treatment of fibrotic disorders.

Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Biodesy develops a novel system to analyze real-time protein function for research and clinical applications.
$20M
Sep 09, 2018
Series C
-
Second Genome is a clinical-stage pharmaceutical company that focuses on developing microbiome-based therapeutics for the treatment of chronical diseases and illness.
$8.4M
Jul 12, 2016
Series B
-
Purigen Biosystems develops a transformative platform that automates the process of extracting, enriching and quantifying nucleic acids.
$26.4M
Mar 03, 2016
Series A
-
Biodesy develops a novel system to analyze real-time protein function for research and clinical applications.
$10M
Jan 20, 2016
Series B
-
Flatiron Health is a healthcare technology company that focuses on accelerating cancer research through clinical data management.
$175M
Jan 05, 2016
Series C
Feb 01, 2018

These are all the companies that Roche has invested in. Roche has invested 18 companies and its latest investment was Promedior, Inc. in Nov 2019. Promedior is a clinical-stage biotechnology company that develops and commercializes novel therapeutics for the treatment of fibrotic disorders.

Roche News

December 12, 2019BioSpace

Roche and Fortelinea to co-market software solutions in US to improve workflow in histology research labs

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has signed a joint marketing agreement in ... See more »
December 12, 2019Pharmafile

Roche's subcutaneous Perjeta/Herceptin combo proves non-inferior to IV formulation in HER2-positive early breast cancer

New Phase 3 data from Roche has shown that its subcutaneously-delivered formulation of Perjeta (pertu... See more »
December 12, 2019FinanzNachrichten

Phase III FeDeriCa Study Meets Primary Endpoint

SOUTH SAN FRANCISCO (dpa-AFX) - Roche Holding AG (RHHBY) said, in the phase III FeDeriCa study, inves... See more »
December 11, 2019Zacks

Roche's (RHHBY) sBLA for Asthma Drug Xolair Accepted by FDA

The FDA accepts Roche's (RHHBY) allergic asthma drug Xolair's sBLA for the treatment of nasal polyps ... See more »
December 11, 2019Seeking Alpha

Roche's Perjeta regimen shows long-term benefit in breast cancer study

See more »
December 11, 2019Medical Device Network

Roche obtains CE mark for blood glucose monitoring app

Roche has secured CE mark for its smartphone app that allows users to measure blood glucose level wit... See more »
December 11, 2019Seeking Alpha

Roche Holding (RHHBY) Presents At 2019 ASH Annual Meeting - Slideshow

See more »

Roche Press Releases

September 25, 2019PR Newswire

West Cancer Center and Research Institute partners with Roche Tissue Diagnostics - Enhancing Patient Care in the Histology Laboratory with Automation

MEMPHIS, Tenn., Sept. 25, 2019 /PRNewswire/ -- West Clinic Cancer Center is holding a ribbon cutting ... See more »
September 3, 2019GlobeNewswire

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

Basel, 3 September 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ON... See more »
June 26, 2019PRWeb

Roche UK Deploys LifeLink Chatbot as Next Generation Medical Information Desk Virtual Assistant

Conversational Messaging Bot Supports FAQs and Collects Adverse Event Data, Achieving 91% User Satisf... See more »
March 14, 2019PR Newswire

Infinity To Initiate MARIO-3, A Phase 2 Multi-Arm Study Evaluating IPI-549 In Front-Line Triple Negative Breast Cancer And Renal Cell Cancer

CAMBRIDGE, Mass., March 14, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today ... See more »
December 11, 2018streetinsider

Roche to develop companion diagnostic test to help identify patients eligible for anti-PD-1 therapy based on biomarker expression, not location, of solid tumors

TUCSON, Ariz., Dec. 11, 2018 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that ... See more »
December 11, 2018centralcharts

Roche to develop companion diagnostic test to help identify patients eligible for anti-PD-1 therapy based on biomarker expression, not location, of solid tumors

TUCSON, Ariz., Dec. 11, 2018 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that ... See more »
December 10, 2018streetinsider

Changes to the Roche Corporate Executive Committee

Basel, 10 December 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Daniel O'Day, CEO R... See more »

Roche Videos

October 25, 2019Roche Youtube Channel

"Reimaging breast cancer | With a new palette of pink" on YOUTUBE

See more »
October 22, 2019Roche Youtube Channel

"The history of a diagnosis | About multiple sclerosis, with Florence and Simona" on YOUTUBE

See more »
July 12, 2019Roche Youtube Channel

"Skin cancer in 60 seconds" on YOUTUBE

See more »
July 10, 2019Roche Vimeo Channel

"Video Memoria Roche" on VIMEO

Cast: Premios Rosenkranz... See more »
July 9, 2019Roche Vimeo Channel

"El impacto del premio Rosenkranz a través de los años" on VIMEO

Cast: Premios Rosenkranz... See more »
July 8, 2019Roche Vimeo Channel

"Evento 2019" on VIMEO

Cast: Premios Rosenkranz... See more »
July 8, 2019Roche Vimeo Channel

"Dr. en Ciencias Guilherme Borges" on VIMEO

Cast: Premios Rosenkranz... See more »

Social Statistics

Headquarters

Grenzacherstrasse 124

Basel, Basel-Country4070

41-61-688-1111

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

F. Hoffman- La Roche Ltd or simply Roche (Six Swiss Exchange, ROG) discovers, develops, and provides diagnostics and therapeutic products and services. Founded in 1986, the company has its headquarters in Basel, Switzerland. With 14 biopharmaceuticals...

CEO

Roche's CEO, Severin Schwan, currently has an approval rating of 76%. Roche's primary competitors are Novartis, Merck & Bristol Myers Squibb.

Website

roche.com

Frequently Asked Questions about Roche

  1. When was Roche founded?

    Roche was founded in 1896

  2. Who is Roche's CEO?

    Roche's CEO is Severin Schwan

  3. How much revenue does Roche generate?

    Roche generates $927.4M in revenue

  4. How much funding does Roche have?

    Roche has historically raised $0 in funding

  5. Where is Roche's headquarters?

    Roche's headquarters is in Basel Basel-Country, CH

  1. How many employees does Roche have?

    Roche has 94,052 employees

  2. What sector does Roche operate in?

    Roche is in Biotechnology

  3. Who are Roche's competitors?

    Roche's top competitors are Novartis, Merck, Bristol Myers Squibb

  4. Who has Roche invested in?

    Roche's has invested in companies such as Biodesy, Second Genome, Purigen
Stay up-to-date with the latest news on Roche